Clinical trial
Safety and Efficacy Study of rhAngiostatin Administered in Combination With…
NCT00049790 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00049790 |
|---|---|
| Title | Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | recombinant human Angiostatin protein, paclitaxel, carboplatin |
| Completion | Dec 1, 2004 |
| First posted | Nov 15, 2002 |
| Last update posted | Jan 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: